EMOLYTIC ANEMIA C h a r l o t t e i l g a r t n e r . NYHMemori a1 Sloan K e t t e r i n g Cancer Center, New ~o r k C i t y .
IVGG treatment h i s hemoglobin rose s l o w l y over 4 weeks frm 7.7 t o 13.9, d e s p i t e tapering o f prednisone, and remains s t a b l e . I n f a n t #2 had h i s second relapse o f immune hemolytic anemia w i t h the hemoglobin decreasing t o 7 gm/dl. Two weeks o f IVGG treatment s t a b i l i z e d h i s hemoglobin; 1% weeks a f t e r treatment was stopped h i s hemoglobin f e l l t o 4.5 g d d l . Reinduction w i t h 5 gm/kg IVGG and continued maintenance r e s t a b i l i z e d h i s hemogl obin a t 7. Both p a t i e n t s had IgG antibodies which f a i l e d t o b i n d t o rH n u l l c e l l s a f t e r e l u t i o n and abnormally decreased i n v i t r o nonspecifi c antibody synthesis. Recent work by Sal ama e t a1 demonstrates t h a t a p a r t o f the RES Fc r e c e p t o r blockade mediating an i ncreased p l a t e l e t count during IVGG treatment o f ITP i s due t o low grade r e d c e l l immune hemolysis; therefore, they s t a t e t h a t AIHA cannot be t r e a t e d by IVGG. We demonstrate t h a t AIHA can be t r e a t e d by IVGG a l b e i t a t h i g h e r dosage than even i n ITP ( 5 gml  kg ' 847 and Margaret W. H i l g a r t n e r . NYH-CUMC Di v. Ped.
Hem/Onco., New York C i t y .
E i g h t p a t i e n t s w i t h acute ITP s t e r o i d r e s i s t a n t (SR) t o 2-4 mglkglday o f prednisone f o r 1 t o 6 weeks received 1 gmlkglday IVGG up t o 3 consecutive days depending on response. The t a b l e compares p l a t e l e t count and IVGG treatments o f the 8 SR p a t i e n t s w i t h 10 p r e v i o u s l y untreated (U) acute ITP p a t i e n t s : P l a t e l e t s l u l ~1 0 .~ Follcwup IVGG i n gmlkg Grou N I n i t i a l Peak Last Months I n i t i a l Maintenance (sRP 8 13 213 218 4.8 1.75 1.5 (U) 10 18 186 204 3.6 1.3 0.8 No SR p a t i e n t s t i l l r e q u i r e s treatment: 5 are i n remission and the 3 non-remission p a t i e n t s average 97,0001~1. The outcome o f the U p a t i e n t s i s 4 remission, 5 s t a b l e w i t h o u t therapy and 1 r e f r a c t o r y ( n o t d i f f e r e n t from the SR group). 4/10 U p a t i e n t s and 2/8 SR p a t i e n t s received o n l y a s i n g l e i n f u s i o n t o t a l ; 3/10 U p a t i e n t s and 118 SR p a t i e n t s received o n l y 2 i n f u s i o n s . Sixteen p a t i e n t s were t r e a t e d w i t h Immuno IVGG, 2 w i t h Sandoglobul i n and no s i d e e f f e c t s were seen. N e i t h e r i n i t i a l p l a t e l e t count, p l a t e l e t size, PAIgG, PAIgM, C3, C*, CHS0 n o r serum immunoglobulin l e v e l s d i f f e r e n t i a t e d the SR vs U groups o r p r ed i c t e d which p a t i e n t s would respond b e t t e r t o IVGG. I n summary, IVGG e f f e c t i v e l y t r e a t e d s t e r o i d r e s i s t a n t acute ITP p a t i e n t s (presumably t h e group a t h i g h e s t r i s k f o r i n t r a c r a n i a l hemorrhage) w i t h r a p i d increases i n t h e p l a t e l e t count and e x c e l l e n t outcomes comparable t o p r e v i o u s l y untreated p a t i e n t s . The only d i f f e r e n c e between the SR & U o t s was the increased use of IVGG. CHILDHOOD MONOSOMY 7 SYNDROME: A FAMILIAL DISORDER?
Link, Karen Backer and B e r t i l E. Glader, Stanford U n i v e r s i t y School o f Medicine, C h i l d r e n ' s H o s p i t a l a t Stanford, Department o f P e d i a t r i c s , D i v i s i o n o f HematologylOncology, Stanford, CA
Preleukemic states are r a r e i n c h i l d r e n although monosomy 7 now i s recognized as a genetic marker f o r a childhood myeloprol i f e r a t i v e d i s o r d e r which evolves i n t o bone marrow (EM) f a i l u r e o r acute nonlymphocytic leukemia (ANLL). Recently we observed a Caucasian g i r l w i t h t h i s disorder. The s a l i e n t f e a t u r e s o f her course included: (1) onset o f pancytopenia a t 9 months o f age, ( 2 ) p e r s i s t e n t granulocytopenia, thrombocytopenia and macrocytos i s (MCV = 108) over a 6 year period, (3) e v o l u t i o n o f marked dyserythropoiesis a t 7 years o f age, ( 4 ) presence o f BM monosomy 7 i n 100% o f metaphases w h i l e PHA s t i m u l a t e d p e r i p h e r a l b l o o d r evealed a 46 XX karyotype, ( 5 ) conversion t o ANLL a t 7-112 years o f age and (8) f a i l u r e t o achieve remission w i t h c u r r e n t l y e f f e ct i v e ANLL chemotherapy. The p a t i e n t ' s h e a l t h y 5 year o l d b r o t h e r a l s o manifested m i l d thrombocytopenia, macrocytosis (MCV = 98) and monosomy 7 i n h i s BM karyotype. The observations described here now b r i n g t o 27 t h e t o t a l number o f reported cases o f c h i l dhood monosomy 7. Of p a r t i c u l a r i n t e r e s t , however, 8 o f these cases represent 4 p a i r s o f s i b l i n g s . I t thus appears t h a t t h e frequency o f f a m i l i a l involvement may approach 30%. For t h i s reason, s i b l i n g s o f these p a t i e n t s should be s e r i a l l y evaluated f o r hematologic dysfunction and chromosomal changes. This i s espec i a l l y important since e f f e c t i v e therapy f o r t h i s c o n d i t i o n may be bone marrow t r a n s p l a n t a t i o n from a histocompatible s i b l i n g . 
i t y of PMNLs t o become b i p o l a r i n s h a p e i n r e s p o n s e t o t h e c h e m o a t t r a c t a n t formyl-methionyl-leucyl-phenyla-
l a n i n e (FMLP) was examined. R e s u l t s from 84 of 90 CL a s s a y s were normal. R e s u l t s were normal r e g a r d l e s s of t i m e s i n c e i n i t i a l r e m i s s i o n o r end of t h e r a p y . Too few p a t i e n t s i n r el a p s e were s t u d i e d f o r s t a t i s t i c a l a n a 1 y s i s . r Abnormal r e s u l t s o c c u r r e d i n 6 p a t i e n t s o n a s i n g l e o c c a s i o n ; t h e r e w e r e n o common f e a t u r e s w i t h r e g a r d t o t i m e from d i a g n o s i s , t r e a t m e n t o r s t a t e of d i s e a s e .
3 of t h e s e 6 had l a t e r measurements which w e r e normal. R e s u l t s from 1 4 of 89 a s s a y s measuring b i p o l a r s h a p e change were abnormal. 11 p a t i e n t s had i n c r e a s e d numbers of b i p o l a r shaped c e l l s p r i o r t o FMLP s t i m u l a t i o n and 3 p a t i e n t s had a b n o r m a l l y low numbers of b i p o l a r PMNLs a f t e r FMLP s t i m u l at i o n . A b n o r m a l i t i e s were found i n 3 of 7 T c e l l and 1 0 of 37 " n u l l " c e l l p a t i e n t s .
No p a t i e n t s were i n f e c t e d a t t h e t i m e of t h e s e s t u d i e s . C o n t r o l s i n c l u d e d c h i l d r e n and a d u l t s n o t h a v i n g c a n c e r . These d a t a s u g g e s t (1) c h i l d r e n w i t h ALL have normal PMNL o x i d a t i v e m e t a b o l i s m i n i n i t i a l r e m i s s i o n and d u r i n g s u b s eq u e n t chemotherapy ( 2 ) 1 3 / 4 5 p a t i e n t s had a b n o r m a l i t i e s i n t h e b i p o l a r s h a p e change a s s a y s u g g e s t i n g t h a t c h e m o t a c t i c a c t i v i t y may b e a d v e r s e l y a l t e r e d .
S t u d i e s of chemotaxis a r e underway.
USE OF MONOCLONAL ANTIBODIES SPECIFIC FOR NEUROBLAS-TOMA (NB) IN THE DETECTION AND COMPLEMENT MEDIATED 850LYSIS
OF MICROSCOPIC DISEASE. Nai-Kong V. a, U l l a S a a r i n e n , Duffy Donovan, Bonnie Landmeier, P e t e r F. e, Case W e s t e r n R e s e r v e U n i v e r s i t y , Rainbow B a b i e s and C h i l d r e n s H o s p i t a l , Department o f P e d i a t r i c s , C l e v e l a n d , Ohio 44106.
a g a i n s t human NB c e l l s u r f a c e a n t i g e n s were e s t a b l i s h e d u s i n g s t a n d a r d h y b r i d i z a t i o n t e c h n i q u e s . Both b y ELISA a n d i m u n of l u o r e s c e n c e , t h e s e monoclonal a n t
i b o d i e s do n o t b i n d t o normal bone marrow (BM) o r p e r i p h e r a l b l o o d c e l l s . They a l l b i n d i nt e n s e l y t o human NB and NB c e l l l i n e s ( e x c e p t SKNSH and SKNMC). The c r o s s r e a c t i v i t y p a t t e r n s w i t h o t h e r s a r c o m a s a n d t h e i
r r e l a t i v e d e g r e e of b i n d i n g s u g g e s t t h a t t h e t h r e e monoclonal a n t i b o d i e s h a v e d i f f e r e n t s p e c i f i c i t i e s a n d a r e n o t r e a c t i n g w i t h common neuro-ectodermal a n t i g e n s . Using i m u n o f l u o r e s c e n c e t h e s e a n t i b o d i e s c a n d e t e c t r e p r o d u c i b l y 10.1% of tumor c e l l s s e e d e d i n B M s a m p l e s . P a t i e n t s w i t h w i d e s p r e a d NB even though n e g a t i v e i n t h e i r B M a s p i r a t e and b i o p s y b y s t a n d a r d l i g h t microscopy a r e o f t e n p o s i t i v e by immunofluorescence i n t h e i r B M a s p i r a t e s w i t h a l l 3 m o n o c l o n a l s . L e s s t h a n 250 n g o f 3A7
o r 3G6 c a n k i l l 100% o f 3x105 NB c e l l s i n t h e p r e s e n c e o f 1 : 8 d i l u t i o n of g u i n e a p i g complement, w h i l e n o t a f f e c t i n g normal b l o o d o r B M c e l l s . I n summary ( 1 ) t h e s e a n t i b o d i e s a p p e a r t o b e u s e f u l i n d e t e c t i n g and m o n i t o r i n g r e s i d u a l NB i n B M s a m p l e s , (2) t h e y a r e p o t e n t c y t o t o x i c a n t i b o d i e s and may b e s u i t a b l e f o r c o m p l e t e and s p e c i f i c removal o f r e s i d u a l NB c e l l s b e f o r e a u t o l o g o u s B M t r a n s p l a n t a t i o n . We d e v e l o p e d a new a n i m a l model t o s t u d y a n t i b i o t i c s y n e r g y i n n e u t r o p e n i a . I n f a n t r a t s were r e n d e r e d n e u t r o p e n i c by 3 i n t r a p e ri t o n e a l ( I P ) 50 mglkg d o s e s of c y t a r a b i n e o v e r 36 h r s . Mean absol u t e n e u t r o p h i l c o u n t s were <300/mm3 on p o s t -t r e a t m e n t d a y s 3-8 and n o r m a l i z e d on d a y s 9-10, w i t h ~1 % m o r t a l i t y . Pseudomonas a e r u g i n o s a (PA) w i t h MICIMBC of Amikacin (A) = 8 / 1 6 ug/ml and N-formimidoyl t h i e n a m y c i n (T) = 418 ug/ml was s t u d i e d ; no s y n e r g y between A and T was d e m o n s t r a t e d by t h e k i l l i n g c u r v e method. N e u t r o p e n i c r a t s , i n o c u l a t e d I P w i t h 2-6x106 CFU of PA (-200 L D S o ) , w e r e t r e a t e d I P 4 h r s l a t e r w i t h : s a l i n e ( S ) ; A 10 mg/kg; T 6.25 mglkg; A + T (same d o s e s ) ; o r ~/ 2 + T/2, e a c h e v e r y 6 h r s f o r 48 h r s . Peak serum l e v e l s of e a h c a n t i b i o t i c were l e s s t h a n t h e MIC/MBC f o r PA. S i x h r s a f t e r t h e l a s t d o s e . s u r v i v a l ( I a l i v e l i i t r e a t e d ) was a s shown: Group S u r v i v a l (%) I n v i v o , b o t h h a l f -d o s e and f u l ld o s e c o m b i n a t i o n t h e r a p y produced s i g n i f i c a n t l y g r e a t e r s u r v i v a l t h a n e i t h e r a e e n t a l o n e . A + T was suoe- 
